Alpine Immune Sciences (FRA:34LA) Short-Term Capital Lease Obligation : €0.87 Mil (As of Mar. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Alpine Immune Sciences Short-Term Capital Lease Obligation?

Alpine Immune Sciences's Short-Term Capital Lease Obligation for the quarter that ended in Mar. 2024 was €0.87 Mil.

Alpine Immune Sciences's quarterly Short-Term Capital Lease Obligation increased from Sep. 2023 (€0.82 Mil) to Dec. 2023 (€0.84 Mil) and increased from Dec. 2023 (€0.84 Mil) to Mar. 2024 (€0.87 Mil).

Alpine Immune Sciences's annual Short-Term Capital Lease Obligation increased from Dec. 2021 (€0.55 Mil) to Dec. 2022 (€0.71 Mil) and increased from Dec. 2022 (€0.71 Mil) to Dec. 2023 (€0.84 Mil).

Alpine Immune Sciences Short-Term Capital Lease Obligation Historical Data

The historical data trend for Alpine Immune Sciences's Short-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alpine Immune Sciences Short-Term Capital Lease Obligation Chart

Alpine Immune Sciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Short-Term Capital Lease Obligation

Get a 7-Day Free Trial

0.54

0.55

0.71

0.84

Alpine Immune Sciences Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Short-Term Capital Lease Obligation	Get a 7-Day Free Trial															0.74	0.77	0.82	0.84	0.87

Alpine Immune Sciences Short-Term Capital Lease Obligation Explanation

Short-Term Capital Lease Obligation represents the total amount of Long-Term Capital Lease Obligation that must be paid within the next accounting period. Capital lease obligations are contractual obligations that arise from obtaining the use of property or equipment via a capital lease contract.

Alpine Immune Sciences Short-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Alpine Immune Sciences's Short-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Alpine Immune Sciences (FRA:34LA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alpine Immune Sciences Inc (FRA:34LA) » Definitions » Short-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

ALPN:USA 34LA:Germany

Address

188 East Blaine Street, Suite 200, Seattle, WA, USA, 98102

Website

https://www.alpineimmunesciences.com

Alpine Immune Sciences Inc is a clinical-stage biopharmaceutical company dedicated to discovering and developing protein-based immunotherapies to treat autoimmune and inflammatory diseases. Its approach includes a proprietary scientific platform that converts native immune system proteins into differentiated, multi-targeted therapeutics. Its pipeline candidates are; ALPN-303, or povetacicept, is a dual antagonist of the B cell activating factor, or BAFF, and a proliferation-inducing ligand, or APRIL, cytokines, which play key roles in the activation, development, and survival of B cells, and ALPN-101, or acazicolcept, is a dual Inducible T cell Costimulator, or ICOS, and CD28 antagonist intended for the treatment of autoimmune and inflammatory diseases.

Alpine Immune Sciences (FRA:34LA) Headlines

No Headlines